

September 8, 2004

**Press Release:**

**Global Genomics' tangerine<sup>®</sup> gene expression profiling method published**

Researchers at Global Genomics<sup>SM</sup> AB (Stockholm, Sweden) are pleased to announce today's publication in the journal Nucleic Acids Research of the tangerine gene expression profiling method. The paper describes the advanced features of tangerine gene expression profiling - unbiased whole genome coverage, automatic combinatorial gene identification and sensitivity down to 7.5 parts per 10 million transcripts - and analyzes performance across multiple experiments.

Citation:

Metsis, et al. (2004) *Whole-genome expression profiling through fragment display and combinatorial gene identification*. Nucleic Acids Research vol. 32, no. 16, **e127**

The paper is freely available through the following link:

<http://nar.oupjournals.org/cgi/content/full/32/16/e127?ijkey=75UQxiVGUfYXI&keytype=ref>

Reprints are available from the company upon request.

**About Global Genomics**

Global Genomics develops and out-licenses innovative tools in functional genomics that provide unique insight into healthy, diseased or drug-treated cells. The company's expertise in advanced molecular biology techniques and computational analysis has resulted in the recent launch of tangerine<sup>®</sup> gene expression profiling, a proprietary solution that reveals a whole genome expression profile in a single experiment.

High coverage and sensitivity ensure complete profiles of expressed genes, giving researchers the ability to study gene regulation in any disease or eukaryotic model, since there is no prerequisite for sequence data. The tangerine technology is based on PCR, capillary electrophoresis, proprietary databases and algorithms that generate gene expression profiles. Incorporating such comprehensive gene expression profiling at key stages in drug discovery significantly improves selection of targets and lead compounds, leading to well-validated drug candidates and expediting development of a strong pharmaceuticals portfolio.

Questions regarding this press release or other issues should be directed to Dr. Sten Linnarsson, Chief Technology Officer, +46 8 50 88 47 18 or Mr. Martin Vidaeus, Manager Market Development, +46 8 50 88 47 29.

Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Although based on the company's current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from those expressed herein. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, as well as various legal hazards.

-----  
The Global Genomics (SM) logo and tangerine (R) are service and registered trademarks, respectively, of Global Genomics AB.